FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Shell William 		2. Issuer Name and Ticker or Trading Symbol

Targeted Medical Pharma, Inc. [ TRGM ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      __ X __ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
CEO & Chief Scientific Officer
(Last)          (First)          (Middle)

C/O TARGETED MEDICAL PHARMA, INC., 2980 BEVERLY GLEN CIRCLE, SUITE 301 		3. Date of Earliest Transaction (MM/DD/YYYY)

4/16/2013
(Street)

LOS ANGELES, CA 90077
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

7/23/2013 
6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, $.001 par value per share   6/20/2013     P    28100   A $1.15   (2) 651054   (2) I   By trust   (1)
Common Stock, $.001 par value per share                  622954   (3) I   By trust   (1)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
( 1)  Common stock and warrants are held by Willliam Shell Survivor's Trust.
( 2)  On July 23, 2013, the reporting person mistakenly filed a Form 4 without including his purchase of 28,100 shares of Targeted Medical Pharma, Inc. Such purchase occurred on June 20, 2013 at a weighted average price of $1.15 per share. These shares were purchased in multiple transactions at prices ranging from $1.00 to $1.20 per share.
( 3)  See Remarks

Remarks:
On July 23, 2013, the reporting person mistakenly filed a Form 4 reporting the purchase of certain shares of Targeted Medical Pharma, Inc. even though such purchases were cancelled prior to delivery. Below is a summary of the purchases that were mistakenly filed on the Form 4:
- 1,500 shares at a price of $4.25 per share on April 23, 2013
- 2,500 shares in multiple transactions at prices ranging from $4.25 to $4.30 per share on April 22, 2013
- 1,000 shares at a price of $4.35 per share on April 19, 2013
- 6,000 shares in multiple transactions at prices ranging from $4.55 to $4.79 per share on April 17, 2013
- 6,000 shares in multiple transactions at prices ranging from $4.38 to $4.90 per share on April 16, 2013

As a result of these canceled purchases, the reporting person beneficially owns 622,954 shares of Targeted Medical Pharma, Inc.'s common stock as opposed to the previously reported amount of shares (639,954 shares).

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Shell William
C/O TARGETED MEDICAL PHARMA, INC.
2980 BEVERLY GLEN CIRCLE, SUITE 301
LOS ANGELES, CA 90077 		X X CEO & Chief Scientific Officer
Elizabeth Charuvastra & William Shell Family Trust
3048 NICADA DRIVE
LOS ANGELES, CA 90077
X


Signatures
/s/ William E. Shell 9/4/2013
** Signature of Reporting Person Date

Elizabeth Charuvastra and William Shell Family Trust dated 9/26/2008,by /s/ William E. Shell, Trustee 9/4/2013
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Targeted Medical Pharma (CE) (USOTC:TRGM)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024 Click aqui para mais gráficos Targeted Medical Pharma (CE).
Targeted Medical Pharma (CE) (USOTC:TRGM)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024 Click aqui para mais gráficos Targeted Medical Pharma (CE).